---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-167882"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:16:32.143814+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte stockholders re-elect three Class III directors, ratify Deloitte, approve say-on-pay

## Summary
- Class III directors Halley Gilbert, Michael Kamarck, and Grant Pickering re-elected with over 61M votes each.
- Ratification of Deloitte & Touche as independent auditor for FY2023 approved with 74.9M for, 3,583 against.
- Non-binding advisory vote on named executive officer compensation approved with 62.9M for, 7.2M against.
- Broker non-votes were 4,802,816 on director election and say-on-pay matters.
- All three proposals passed as recommended by the board.

## SEC filing metadata
- accession: 0001193125-23-167882
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000119312523167882/0001193125-23-167882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000119312523167882/d456008d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-167882
- JSON: https://secwatch.observer/filing/0001193125-23-167882.json
- Plain text: https://secwatch.observer/filing/0001193125-23-167882.txt

## Key facts
- Shareholder Votes
  Vaxcyte, Inc. shareholders approved Approval, on a non-binding, advisory basis of the compensation of the Company's named executive officers. at the 2023-06-13 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: 3. The approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers. The approval of the non-binding resolution on named executive officer compensation was approved by the votes indicated: For Against Abstain Broker Non-Votes 62,915,437 7,157,815 54,191 4,802,816
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523167882/0001193125-23-167882-index.htm
- Shareholder Votes
  Vaxcyte, Inc. shareholders approved Election of three nominees to serve as Class III directors until the Company's 2026 Annual Meeting of Stockholders and until their successors have been duly elected and qualified. at the 2023-06-13 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: 1. The election of three nominees to serve as Class III directors until the Company’s 2026 Annual Meeting of Stockholders and until their successors have been duly elected and qualified, or, if sooner, until the director’s death, resignation or removal. The following three Class III directors were re-elected by the votes indicated: For Withheld Broker Non-Votes Halley Gilbert, J.D. 61,216,757 8,910,686 4,802,816 Michael E. Kamarck, Ph.D. 69,655,830 471,613 4,802,816 Grant E. Pickering, M.B.A. 69,813,142 314,301 4,802,816
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523167882/0001193125-23-167882-index.htm
- Shareholder Votes
  Vaxcyte, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-06-13 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-13
  source text: 2. The ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The appointment was ratified by the votes indicated: For Against Abstain 74,913,275 3,583 13,401
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000119312523167882/0001193125-23-167882-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.